Japan’s iPSC Cell Therapy Approvals: Two Landmark Drugs in February 2026

Updated on March 20,2026|Written by Patsnap Team

In February 2026, Japan’s Ministry of Health, Labour and Welfare (MHLW) approved two allogeneic iPSC-derived cell therapies in the same month — Raguneprocel (branded Amchepry, Sumitomo Pharma) for Parkinson’s disease and the iPSC-derived cardiomyocyte product ReHeart (Cuorips, Inc.) for heart failure. These are the world’s first commercial approvals of iPSC-based therapies.

This is not an incremental regulatory milestone. It represents the translation of foundational iPSC science — pioneered in Japan by Nobel laureate Shinya Yamanaka — into regulated clinical products, and carries direct implications for how iPSC-derived therapies will be developed and approved globally.

All data is sourced from Patsnap Synapse, an AI-powered drug intelligence platform tracking global regulatory activity, patent estates, and clinical pipelines.

What Are iPSC-Derived Cell Therapies?

Induced pluripotent stem cells (iPSCs) are adult somatic cells reprogrammed to a pluripotent embryonic-like state through the expression of transcription factors (originally OCT4, SOX2, KLF4, and c-MYC in Yamanaka’s 2006 landmark work). From this state, iPSCs can be differentiated into virtually any cell type: neurons, cardiomyocytes, hepatocytes, and more.

Allogeneic iPSC therapies — the modality for both February approvals — derive from donor cells rather than the patient’s own. This enables off-the-shelf manufacturing: one donor iPSC line can produce therapeutic batches for many patients, substantially lowering cost and logistical complexity compared to autologous approaches.

The key challenge is immunological: donor-derived cells risk rejection. Japan has addressed this through HLA-homozygous donor iPSC banks developed at Kyoto University’s Centre for iPS Cell Research and Application (CiRA), which can match the HLA haplotypes of a large proportion of the Japanese population using a small number of carefully selected donor lines.

Monitor competitor pipeline movements and patent expiry timelines before anyone else with Patsnap Synapse. Get started →

Raguneprocel (Amchepry) — iPSC-Derived Neurons for Parkinson’s Disease

Approval date: March 6, 2026 (MHLW formal grant; February recommendation)
Developer: Sumitomo Pharma Co., Ltd. / RACTHERA Co., Ltd.
Branded name: Amchepry
Drug type: Allogeneic iPSC-derived dopaminergic neural progenitor cells
Indication: Improvement of motor symptoms in Parkinson’s disease patients with inadequate response to pharmacological therapies including levodopa
Regulatory pathway: Conditional and time-limited approval (7 years)

The disease

Parkinson’s disease is the second most common neurodegenerative disorder, affecting approximately 10 million people worldwide. Its core pathology is the progressive loss of dopaminergic neurons in the substantia nigra, reducing dopamine signalling in the nigrostriatal pathway and producing the hallmark motor symptoms — bradykinesia, rigidity, resting tremor, and postural instability. Existing therapies (levodopa, dopamine agonists, MAO-B inhibitors) address symptoms but do not restore lost neurons or halt progression.

The mechanism

Raguneprocel delivers iPSC-derived dopaminergic progenitor cells into the putamen via stereotactic neurosurgical injection. The goal is cell replacement: transplanted neurons engraft, mature, and restore dopaminergic tone. This approach builds on decades of fetal midbrain transplantation research from the 1980s–1990s, which proved proof of concept but was limited by tissue scarcity and inconsistent outcomes.

The therapy uses cells differentiated from a clinical-grade iPSC line (QHJI01s04) homozygous for a common Japanese HLA haplotype. The Phase I/II clinical trial results — conducted at Kyoto University Hospital in seven patients — were published in Nature in April 2025. Sumitomo Pharma submitted for MHLW marketing authorization in August 2025 based on that investigator-initiated study.

The Michael J. Fox Foundation described the approval as “a significant scientific milestone for the Parkinson’s community”, while noting that it is not currently available to US patients and that larger confirmatory studies are required to establish efficacy in a broader population. Nature’s news coverage notes that some researchers have expressed caution about the limited evidence base underpinning a conditional approval.

The official Sumitomo Chemical/RACTHERA announcement is available at MarketScreener.

Tracking iPSC pipeline developments, patent estates, and regulatory filings globally? Patsnap Synapse maps cell therapy programs across every indication and development stage. Explore the iPSC pipeline on Synapse →

ReHeart (Cuorips) — iPSC-Derived Cardiomyocytes for Heart Failure

Approval date: February 21, 2026
Developer: Cuorips, Inc.
Drug type: Allogeneic iPSC-derived cardiomyocyte cell therapy
Indication: Heart failure
Regulatory pathway: Conditional and time-limited approval

The disease

Heart failure affects over 64 million people globally and is a leading cause of hospitalisation in adults over 65. The condition is characterised by the heart’s inability to pump sufficient blood to meet metabolic demand — most commonly following ischaemic injury that destroys cardiomyocytes, cells with very limited natural regenerative capacity in adult humans. Current treatment includes guideline-directed medical therapy (ACE inhibitors, beta-blockers, SGLT2 inhibitors, MRAs) and, in advanced cases, heart transplantation. Cardiac cell therapy has been investigated for decades with mixed results from earlier mesenchymal stem cell trials.

The mechanism

Cuorips delivers allogeneic iPSC-derived cardiomyocytes to injured myocardium with the goal of restoring contractile function. A known challenge in the field is the immature, fetal-like phenotype of iPSC-derived cardiomyocytes — smaller than adult cells, with less organised sarcomere structure and spontaneous automaticity. Addressing maturation and electrophysiological integration has been a primary focus of current-generation programs.

As reported by Nature, both Japan’s iPSC approvals have generated scientific debate over the sufficiency of evidence from small Phase I/II studies to support conditional approval.

Why Japan Is Leading in iPSC Regulation

Several structural factors have positioned Japan ahead of the FDA and EMA in iPSC regulatory precedent:

The Act on the Safety of Regenerative Medicine (2014) established a tiered framework for cell and gene therapies more permissive than Western equivalents, allowing conditional approval based on early clinical data with post-market confirmatory requirements.

The Sakigake designation (launched 2015) provides priority review and targeted 6-month timelines for regenerative and advanced medical products. Both February approvals are understood to have progressed under this framework.

CiRA’s HLA-homozygous donor iPSC bank, developed with ongoing Japanese government funding via AMED, provides practical foundation for allogeneic iPSC product development in Japan.

Proximity to foundational science — CiRA and Kyoto University have been directly involved in translational development — has given Japanese developers a significant head start in process development and regulatory dialogue. Background on Japan’s regulatory innovation in this area is covered in Nature’s news analysis.

Patsnap Synapse tracks every approval and ERP designation across FDA, NMPA, EMA, and PMDA in real time — connected to patent, clinical trial, and competitive data. Explore regulatory intelligence →

Global Implications

These approvals are likely to influence regulatory thinking outside Japan:

• Evidence package benchmarking: The data packages accepted by MHLW — largely from small Phase I/II studies — will inform expectations at FDA and EMA for future submissions. However, the conditional nature of approval and the 7-year confirmatory requirement signal that MHLW itself is not treating small-trial data as sufficient for unrestricted market access.
• Allogeneic iPSC precedent: Regulatory acceptance of off-the-shelf allogeneic iPSC products in neurology and cardiology may accelerate parallel programs in retinal dystrophy, spinal cord injury, and blood disorders.
• Scientific caution: As Nature reports, some researchers are concerned that the therapies are not yet adequately supported by clinical data. Sham-controlled Phase 3 trials will be necessary to establish efficacy rigorously — and Japan has prior precedent for conditional approvals being withdrawn when post-market confirmatory evidence was insufficient (HeartSheet was withdrawn in 2024).

iPSC Therapies: What’s Next in the Global Pipeline

Beyond Japan, several allogeneic iPSC programs are in clinical development:

The next 24–36 months are likely to determine whether Japan’s conditional approvals translate into confirmatory efficacy — and whether the FDA and EMA move to accept comparable evidence packages for their first iPSC submissions.

Patsnap Synapse provides comprehensive cell therapy pipeline intelligence — iPSC clinical trials, differentiation protocol patents, developer profiles, and regulatory history — across all indications and geographies. Start exploring the regenerative medicine pipeline on Synapse →

Monthly drug approvals, ERP designations, competitor pipeline shifts — Patsnap Synapse helps drug development and BD teams stay ahead of the curve. Request a demo →

Further Reading

• Global drug approvals roundup — February 2026
• US & EU drug approvals — February 2026
• APAC drug approvals — China and South Korea, February 2026
• What are FDA Accelerated Approval and RMAT designations?

Data sourced from Patsnap Synapse. Regulatory classifications reflect filings as of February–March 2026. This post is for informational purposes only and does not constitute clinical advice.